Melanoma Drug's hidden effect on moles revealed in new study

NCT ID NCT06599619

Recruiting now Knowledge-focused Sponsor: John Kirkwood Source: ClinicalTrials.gov ↗

First seen Jan 29, 2026 · Last updated May 22, 2026 · Updated 14 times

Summary

This study looks at how a standard melanoma immunotherapy (anti-PD1) changes the appearance and biology of atypical moles in people with stage IIB-IIIC melanoma. About 30 participants with at least two atypical moles will be followed to see if the treatment alters mole size, color, or cellular features. The goal is to better understand the drug's effects beyond treating the main cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact

Conditions

Explore the condition pages connected to this study.

MELANOMA